A retrospective analysis on anti-CD20 antibody–treated Epstein–Barr virus–related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation
A retrospective analysis on anti-CD20 antibody–treated Epstein–Barr virus–related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation
复制标题
基于 ATG 的半相合 T 充足造血干细胞移植后抗 CD20 抗体治疗的 Epstein Barr 病毒相关移植后淋巴细胞增殖性疾病的回顾性分析
DOI：
10.1007/s00277-020-04003-8
复制
发表时间：
2020-03
影响因子：
3.5
通讯作者：
Xiao-Jun Huang
中科院分区：
文献类型：
--
作者：
Xue-Yi Luo;Xiao-Dong Mo;Lan-Ping Xu;Xiao-Hui Zhang;Yu Wang;Kai-Yan Liu;Ying-Jun Chang;Xiang-Yu Zhao;Xiao-Jun Huang
Posttransplantation lymphoproliferation disorder (PTLD) is a life-threatening complication after hematopoietic stem cell transplantation (HSCT). Anti-CD20 antibody is the most widely used antibody to eliminate infected B cells. Few studies have focused on prognostic factors predicting the outcome of EBV (Epstein–Barr virus)-PTLD. We conducted a retrospective analysis of 2571 haplo-HSCTs performed between 2010 and 2017 at the Peking University Institute of Hematology; seventy patients who had been treated with rituximab for PTLD were enrolled. The overall EBV-related PTLD frequency was 3.1%. With a median follow-up time of 365 days (range, 54–2659), the overall survival rate was 51.43% (36/70). The cumulative incidence of EBV-PTLD complete remission with anti-CD20 antibody monotherapy was 68.57% (48/70). EBV-PTLD-related mortality was 11.43% (8/70), while the transplantation-related mortality was 38.57% (27/70). Multivariate analysis showed that a decrease in EBV viral load 1 week after therapy was associated with high response rate of EBV-PTLD (p= 0.007, 0.106 (0.021–0.549)), low PTLD-related mortality (p= 0.010, HR 0.058 (0.007–0.503)), and transplantation-related mortality (p= 0.051, HR 0.441 (0.194–1.003)). For EBV-PTLD patients after haplo-HSCT who received rituximab as first-line therapy, non-decreased EBV viral load 1 week after anti-CD20 therapy could be high risk factor for poor outcomes.
登录
查看更多内容
影响因子：
6.2
作者：
Cesaro, Simone;Pegoraro, Anna;Messina, Chiara
通讯作者：
Messina, Chiara
DOI：
10.1016/b978-012088451-3/50029-6
发表时间：
2006-01-01
期刊：
IMMUNE RESPONSE: BASIC AND CLINICAL PRINCIPLES
影响因子：
--
作者：
Mak, Tak W.;Saunders, Mary E.
通讯作者：
Saunders, Mary E.
影响因子：
20.3
作者：
Stevens, SJC;Verschuuren, EAM;Middeldorp, JM
通讯作者：
Middeldorp, JM
同种异体干细胞移植后EB病毒血症的分子监测和逐步抢先治疗
影响因子：
12.8
作者：
Liu, Qifa;Xuan, Li;Huang, Xiaojun
通讯作者：
Huang, Xiaojun
影响因子：
1.9
作者：
S. Meyer;M. Medinger;J. Halter;H. Baldomero;H. Hirsch;A. Tzankov;S. Dirnhofer;J. Passweg;A. Tichelli
通讯作者：
S. Meyer;M. Medinger;J. Halter;H. Baldomero;H. Hirsch;A. Tzankov;S. Dirnhofer;J. Passweg;A. Tichelli